Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2024-01-01 Epub Date: 2024-02-05 DOI:10.1080/07357907.2024.2308172

Cedric Lebacle, Aydin Pooli, Brian Shuch, Nagesh Rao, Karim Chamie, Nils Kroeger, Izak Faiena, Sandy Liu, Erika L Wood, Arie Belldegrun, Alexandra Drakaki, Allan J Pantuck

引用次数: 0

Abstract

Approximately 65% of renal cell carcinomas (RCC) are diagnosed at a localized stage. We investigated the chromosome 5q gain impact on disease-free survival (DFS) in RCC patients. Overall, 676 patients with stages 1-2 RCC and having cytogenetic analysis were included. Gain of 5q was observed in 108 patients, more frequently in clear cell (ccRCC) than non-clear cell tumors. Gain of 5q is likely an independent prognostic factor since the concerned patients had a decreased recurrence risk in stages 1-2 RCC, confirmed in multivariable analysis. Detecting 5q gain could enhance recurrence risk assessment, allowing tailored post-surgery surveillance, and reducing unnecessary treatments.

查看原文本刊更多论文

5q 染色体增益预示局部肾细胞癌的良好预后

约 65% 的肾细胞癌 (RCC) 在确诊时处于局部阶段。我们研究了染色体5q增益对RCC患者无病生存期（DFS）的影响。我们共纳入了 676 例 1-2 期 RCC 并进行了细胞遗传学分析的患者。在108例患者中观察到了5q增益，在透明细胞（ccRCC）肿瘤中的发生率高于非透明细胞肿瘤。5q增益很可能是一个独立的预后因素，因为相关患者在1-2期RCC中的复发风险降低，这一点在多变量分析中得到了证实。检测5q基因增殖可加强复发风险评估，从而进行有针对性的术后监测，减少不必要的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.